Assmann I
Z Gesamte Inn Med. 1985 Jun 1;40(11):335-41.
In 23 patients with symptomatic severe supraventricular and ventricular tachyarrhythmias the effectiveness and the side effects of a long-term therapy with the class III antiarrhythmic drug Amiodarone (Cordarone) in a dosage of 100-800 mg/die in monotherapy and combination therapy were investigated. In these cases it proved to be an excellently effecting antiarrhythmic drug in tachycardiac dysrhythmias at atrial and ventricular level with an altogether good tolerance. In 16 patients side effects appeared and above all concerned corneal micro-deposition without any clinical symptoms (10 patients). In 3 patients nuclear-medically insignificant changes of the function of the thyroid gland were found--also without clinical relevance. Three times a photosensitisation was conspicuous, only in one patient the therapy was finished on account of epigastric trouble after three months. Av-blockings of higher degree, particularly with bundle-branch block and severe sinus bradycardias as well as disturbances of the thyroid function are regarded as contraindications without preceding pacemaker implantation.
对23例有症状的严重室上性和室性快速心律失常患者,研究了Ⅲ类抗心律失常药物胺碘酮(可达龙)剂量为100 - 800毫克/日的单药治疗和联合治疗的长期疗效及副作用。在这些病例中,它被证明是一种对心房和心室水平的快速心律失常有极佳疗效的抗心律失常药物,总体耐受性良好。16例患者出现了副作用,主要是角膜微沉积但无任何临床症状(10例)。3例患者发现甲状腺功能有核医学检查无显著意义的变化——也无临床相关性。有3次出现明显的光敏反应,仅1例患者因3个月后出现上腹部不适而终止治疗。高度房室传导阻滞,尤其是伴有束支传导阻滞和严重窦性心动过缓以及甲状腺功能紊乱,在未预先植入起搏器的情况下被视为禁忌证。